Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In
  • Log Out

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
  • Log Out
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Author Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on RSS
Research ArticleArticle

Adverse Effects of Topical Nonsteroidal Antiinflammatory Drugs in Older Adults with Osteoarthritis: A Systematic Literature Review

UNA E. MAKRIS, MINNA J. KOHLER and LIANA FRAENKEL
The Journal of Rheumatology June 2010, 37 (6) 1236-1243; DOI: https://doi.org/10.3899/jrheum.090935
UNA E. MAKRIS
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: una.makris@yale.edu
MINNA J. KOHLER
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
LIANA FRAENKEL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

Objective. To systematically review the literature on reported adverse effects (AE) associated with use of topical nonsteroidal antiinflammatory drugs (NSAID) in older adults with osteoarthritis (OA).

Methods. A systematic search of Medline (1950 to November 2009), Scopus, Embase, Web of Science, Cochrane databases, Dissertation and American College of Rheumatology meeting abstracts was performed to identify original randomized controlled trials, case reports, observational studies, editorials, or dissertations reporting AE from topical NSAID in older adults with OA. Information was sought on study and participant characteristics, detailed recording of application site, and systemic AE as well as withdrawals due to AE.

Results. The initial search yielded 953 articles of which 19 met eligibility criteria. Subjects receiving topical NSAID reported up to 39.3% application site AE, and up to 17.5% systemic AE. Five cases of warfarin potentiation with topical agents were reported, 1 resulting in gastrointestinal bleeding. In formal trials, the withdrawal rate from AE ranged from 0 to 21% in the topical agents, 0 to 25% in the oral NSAID, and 0 to 16% in the placebo group.

Conclusion. Although topical NSAID are safer than oral NSAID (fewer severe gastrointestinal AE), a substantial proportion of older adults report systemic AE with topical agents. The withdrawal rate due to AE with topical agents is comparable to that of oral NSAID. Given the safety profile and withdrawal rates described in this study, further data are needed to determine the incremental benefits of topical NSAID compared to other treatment modalities in older adults with OA.

  • ADVERSE EFFECTS
  • TOPICAL ADMINISTRATION
  • NONSTEROID ALANTIINFLAMMATORY AGENTS
  • AGED
  • OSTEOARTHRITIS

Osteoarthritis (OA) is common in older adults1–3 and contributes to significant disability and loss of independence in this population. There is no cure for this disease and treatments focus on symptomatic relief, reducing disability, and improving quality of life4. Nonsteroidal antiinflammatory drugs (NSAID) are widely used in the treatment of OA in older adults despite the increased risk of toxicity in this population5. The OA Research Society International6 and the American Academy of Orthopaedic Surgeons7 recent guidelines support topical NSAID as an effective adjunct or alternative to oral NSAID for treatment of knee OA. Although the safety of topical NSAID in older adults with OA has not been extensively studied, these agents have been widely used outside the United States as a presumably safe alternative for treatment of OA. The first agent, 1% diclofenac sodium, was approved in October 2007 for use in the United States.

Data suggest that some topical NSAID have comparable or somewhat lower efficacy than their oral counterparts8–13. Even if less effective, however, these agents are a reasonable treatment option if their safety profile is superior to that of oral NSAID. This is particularly true for older adults with OA, for whom data show that patients prefer safer medications, even if less effective14.

Although considerable data have been published on the safety of oral NSAID, less is known regarding the safety of topical NSAID specifically in older adults with OA15–23. Given the burden of OA in older adults and the potential toxicities with NSAID administration, we undertook a review of the literature regarding the safety of topical agents to help inform patients and healthcare providers on safe prescribing practices. Because of the heterogeneity of the data on this topic, we were unable to conduct a metaanalysis. Rather, this report is presented as a systematic review of the literature.

MATERIALS AND METHODS

A systematic search of Medline (1950 to November 2009), Scopus (including Embase), Web of Science, Cochrane databases, Dissertation abstracts and American College of Rheumatology meeting abstracts was performed to identify original randomized controlled trials (RCT), case reports, observational studies, letters, editorials, or dissertations reporting AE from topical NSAID in older adults with OA. Nonrandomized trials including case reports or case series were included since we wanted to identify all potential AE related to topical NSAID use. Relevant metaanalyses were reviewed; however, only original publications were included in this study. Bibliographies from all identified review articles and original articles were also reviewed for possible inclusion in the study.

Search strategy

The databases listed above were searched using variations of the following search strategy. The Medline search (via Ovid) included combinations of exploded Medical Subject Heading (MeSH) terms relevant to the drug class of interest (antiinflammatory agents, nonsteroidal, cyclooxygenase inhibitors), the drug administration (administration, topical, oral, pharmaceutical solutions, placebos, drug administration), the disease of interest (osteoarthritis, arthralgia, arthritis), the population of interest (aged, elderly), and, searching MeSH subheadings and textwords (side effects, adverse effects, chemically induced, NSAIDs, topical, gels, solutions, solvents, placebo, aged, elderly, geriatrics, seniors). The search strategy for Scopus and Web of Science was adjusted for the syntax appropriate for each database (see Appendix).

Selection criteria

Exclusion criteria for title and abstracts (Tier 1)

Titles and abstracts identified from the initial review of the literature were excluded if the following criteria were met: (1) unrelated to topical NSAID; (2) unrelated to OA; (3) the title, abstract, and full text of the article were not available in English; (4) no abstract available; (5) the treatment groups were taking both oral and topical NSAID; (6) more than 1 indication for NSAID. For promising titles and abstracts with insufficient information, the full text was retrieved to review the Methods section in detail.

Exclusion criteria for articles (Tier 2)

Full-text articles for titles and abstracts not meeting the above exclusion criteria were reviewed and excluded from the analysis if they fulfilled the following criteria: (1) mean age < 60 years old; (2) study duration < 2 weeks (“several” was assumed to be more than 2); (3) no mention of AE or inability to assign the AE to the study participant with OA.

Data abstraction

Two authors (MK and UM) used a standardized form to independently abstract data from each accepted article. Information was sought on study design, participant demographics, comorbidities, OA severity, number of target joints treated, frequency and amount of applied drug or placebo, detailed recording of application site, and systemic AE as well as withdrawals due to AE. An informal method was used among the authors to achieve consensus when discrepancies arose.

RESULTS

The initial search yielded 1048 citations, of which 95 were duplicates. Of the remaining 953 citations, 19 met our inclusion criteria and are described in this report8–11,13,24–37. The majority of excluded articles in Tier 1 did not include a topical NSAID for the treatment of OA and many trials evaluated oral or topical NSAID for the treatment of non-OA conditions. Figure 1 depicts the process of the search strategy.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

The process of the search strategy. NSAID: nonsteroidal antiinflammatory drug; OA: osteoarthritis; AE: adverse effect; RCT: randomized controlled trial.

Study characteristics

Of the 19 publications meeting eligibility criteria, 16 were RCT: 2 two-arm trials compared a topical to oral NSAID8,10; 2 three-arm trials compared a topical to oral NSAID and placebo9,11; one five-arm trial compared topical to oral NSAID, vehicle [dimethylsulfoxide (DMSO)], and placebo13; 2 RCT compared different topical agents34,35; and 9 compared a topical NSAID to either a vehicle or placebo24–26,29–33,37. Of the remaining 3 publications, one was a case series36 and 2 were case reports27,28.

The duration of RCT ranged from 2 to 12 weeks. Three of the 16 RCT were of 12 weeks’ duration10,13,33. In the 16 RCT, a total of 4428 subjects were randomized; 2043 subjects received a topical NSAID, 790 received an oral NSAID, 735 received the vehicle, and 860 received a placebo topical/oral agent or another topical agent35. Table 1 shows each study design and duration, type and frequency of intervention, and control groups used, as well as sample sizes.

View this table:
  • View inline
  • View popup
Table 1.

Characteristics of trials comparing efficacy and safety of topical NSAID vs oral NSAID vs placebo for OA.

The site of OA in 14 of 16 RCT included the knee; 2 trials evaluated hand OA35,37. In 7 of the RCT, subjects were permitted to treat more than one affected joint9–11,24,25,33,37. Among the RCT, the measurement tools for documenting pain and physical function scores varied and included the Western Ontario and McMaster Universities Osteoarthritis Index [WOMAC; visual analog scale (VAS) or Likert scale], Lequesne index of severity (knee) and algofunctional index, Husskison’s VAS, and Goldberg’s knee score, among others tools. The quality of RCT also varied. The Jadad score38 uses a 5-point scale (0–2 = low, 3–5 = high) to assess the quality of clinical trials based on randomization, blinding, and accountability of all patients including withdrawals. Using the Jadad scale, 10 of the 16 RCT scored a five, 2 scored a four, 2 scored a three, and 2 scored a two.

Participant characteristics

The mean age of participants varied between 60 and 67 years. The range of the proportion of females among the RCT was 52% to 91%. Reporting of exclusion criteria varied among the 16 RCT. Eight RCT10,11,13,24–26,33,34 documented detailed exclusion criteria based on risk factors for oral NSAID-induced toxicity32 including corticosteroid use, known sensitivity to NSAID or ASA30, renal, hepatic and/or peptic ulcer disease8, history of gastrointestinal (GI) bleeding within 3 years of the study31, clinical or laboratory evidence of a hematopoietic disorder30,31, history of alcohol or drug abuse, and known skin disease at the application site8,30,35. Comorbid conditions were mentioned only in the case series and case reports, where 5 subjects were anticoagulated for cardiac valve replacements and one subject had known chronic venous leg ulcers.

Of the 16 RCT, one study13 described concomitant use of GI protection; participants were allowed to continue stable treatment or start treatment with a proton-pump inhibitor if a GI AE occurred during the trial. Nearly all the RCT (14 of 16) allowed the use of acetaminophen (≤ 2–4 grams) for breakthrough pain. Six of the 16 RCT permitted ASA (≤ 325 mg/day) for cardiovascular prophylaxis10,13,24,25,33,35.

Safety

Methods used to report AE varied widely among RCT and included patient report (daily vs weekly), diary assessments, questionnaires, clinical observation, and/or blood testing. The ranges of subjects in the RCT reporting application site and systemic AE are listed in Tables 2 and 3, respectively.

View this table:
  • View inline
  • View popup
Table 2.

Application site adverse effects among RCT.

View this table:
  • View inline
  • View popup
Table 3.

Systemic adverse events among RCT.

Of the application site AE, dry skin, erythema, irritation, paresthesias, and pruritus were reported most commonly, especially among the topical NSAID, vehicle, and placebo groups. Of the systemic AE, GI complaints and headache were reported most frequently, among both topical and oral NSAID groups. Anemia, liver function test and renal abnormalities, and “severe” GI AE (defined as events that produced significant impairment of functioning or incapacitation and were a definite hazard to patient’s health)10 were more numerous among oral NSAID users.

The case series36 and one of the case reports27 describe the potentiation of warfarin anticoagulation with methylsalicylate ointment (manifested as a rise in International Normalized Ratio) in 5 subjects resulting in GI bleeding in one subject. The other case report28 described allergic contact dermatitis from the buffering agent, isopropanolamine, in Traxam gel (confirmed by patch testing) in one subject with known chronic venous stasis ulcers.

The proportion of withdrawals from AE and perceived lack of efficacy are listed in Table 4.

View this table:
  • View inline
  • View popup
Table 4.

Range of proportion of withdrawals from randomized controlled trials due to adverse effects and perceived lack of efficacy.

DISCUSSION

To our knowledge this is the first systematic review evaluating the safety of topical NSAID in older adults with OA. Evans and colleagues published a review on tolerability of topical NSAID in the elderly22 reiterating that previous studies have shown a preponderance of local skin sensitivity, contact dermatitis, and photodermatitis with topical NSAID use. The authors summarized their record-linkage case-control study from Scotland, with 1103 patients (78% were “aged over 50 years”), on the risk of upper GI bleeding and perforation associated with topical NSAID use. They concluded that there was no significant independent association between exposure to topical NSAID and upper GI toxicity [adjusted odds ratio for concomitant oral NSAID use and ulcer-healing drugs was 1.06 (95% CI 0.6–1.88)]23. Further, in their review, Evans and colleagues22 report unpublished data from a similar analysis evaluating patients over age 65 years, suggesting that in older adults topical NSAID may convey a slightly higher risk of GI AE (adjusted OR 1.78, 95% CI 0.91–3.46). These case-control studies had several limitations, as they did not control for medical history of GI events. Also, the authors were unable to adequately determine the temporal relationship between exposure to topical NSAID and GI toxicity.

Altman and colleagues recently presented results (in abstract form) from post hoc analyses of pooled data from 3 similar 12-week randomized double-blind parallel-group multicenter trials comparing safety and efficacy of topical diclofenac 1% gel with vehicle in subjects aged < 65 years and ≥ 65 years with knee OA. They found that application site AE occurred in 5.6% and 8.8% of patients treated with topical diclofenac aged < 65 and ≥ 65 years, respectively. The rates of GI AE were similar in both treatment and age groups (range between 4.0% and 5.1%). The authors concluded that topical diclofenac was generally well tolerated, with similar AE rates in participants < 65 and ≥ 65 years of age (unpublished observations).

Previous metaanalyses evaluating topical NSAID focused on subjects with sports injuries, musculoskeletal pain (acute and chronic), or inflammatory arthritis39–45 who typically were younger than age 65 years. These reviews concluded that topical NSAID are a safe alternative to oral NSAID. In the present review, several findings suggest that there may be additional safety concerns associated with the use of topical NSAID in older adults with OA.

In our systematic review, topical NSAID users reported fewer severe GI events (as defined above) compared to oral NSAID users; however, we found that up to 39.3% of older adults reported an application site AE and, despite the low (6%) systemic absorption of topical NSAID46,47, up to 15% reported a GI-related systemic AE with these agents. Moreover, in the studies reviewed, the withdrawal rate due to AE with topical agents was comparable to that of oral NSAID.

Topical NSAID differ by the active medication, vehicle components, formulations (gel, solution, cream, plaster, patch), and presence of a penetration enhancer (which improves transdermal drug delivery). Any of these components may contribute to application site toxicity. As suggested in the literature, and corroborated in our review, the vehicle or carrier may contribute to the toxicity associated with topical NSAID25, as seen with the application site reactions due to DMSO. Other AE, such as halitosis and body odor, may also result from application of DMSO from the metabolite dimethyl sulfide producing a garlic-like odor25. The withdrawal rate of participants receiving the vehicle arm, containing DMSO, was reported by up to 8% due to AE and up to 26% for perceived lack of efficacy. In the case report by Cooper and Shaw28, patch testing revealed the buffering agent, isopropanolamine, to be the culprit for allergic contact dermatitis rather than the NSAID itself. The methods by which AE are reported in these trials do not permit a detailed analysis of toxicity by dose; this is important especially for RCT that allowed for more than one joint to be treated. Lastly, we found a comparable withdrawal rate due to AE between the topical and oral NSAID groups. Together, these data suggest that topical NSAID are not entirely safe in this patient population.

There are several limitations to our review. First, because of the wide range of study designs used in RCT we were unable to perform quantitative analyses to better define the specific risks associated with topical NSAID. Second, this review is unable to comment on topical NSAID safety in specific subgroups of older adults. The RCT included in this analysis did not identify subsets of older populations (for example, age ranges 65–74, 75–84, 85+), nor did they focus recruitment solely on older populations. We chose a mean age of 60 years as the cutoff definition for “elderly,” as only 3 publications28,31,32 fulfilled our criteria with the more stringent age criterion of 65 years. This finding corroborates previous research on deficiencies in reporting of age data in clinical trials of arthritis as well as underrepresentation of elderly in OA clinical trials10,48,49.

The design of the RCT, while appropriate to examine efficacy, may limit the ability to draw statistical conclusions about safety. In older adults, where multiple comorbidities are frequent, reporting of risk factors and concomitant medication use is critical. Moreover, RCT frequently exclude subjects with risk factors for NSAID-induced toxicity (as required by regulators and ethics review boards), thus likely underestimating the AE profile we may expect to see in the general older adult population. “Real-world” trials comparing topical agents to placebo would be more likely to have generated data relevant for patients most in need of a safer alternative to oral NSAID.

Another study limitation is the lack of uniformity in recording and reporting of AE. The reporting of specific AE varied considerably between studies, resulting in ambiguity in interpreting some of the groups of AE. For example, several studies used AE categories such as “GI NOS,” “Upper GI NOS,” “Rash” without including the specific signs or symptoms. We reported the AE results as ranges because of the heterogeneity among the studies; however, the ranges do not take into account the quality of the studies (as described in the Results section). We sought to identify any AE that was reported in the studies. In addition, although 7 RCT allowed topical NSAID to be used for multiple joints, and the trials varied in the number of topical applications per day, the data are insufficient to permit evaluation of a possible dose effect.

Other specific limitations were encountered while initially creating selection criteria for inclusion into this review. Several publications were excluded because they did not differentiate between participants receiving topical NSAID and those receiving oral NSAID. The authors acknowledge that considerable literature exists on several other topical NSAID and their toxicity/safety (i.e., ketoprofen and photoallergy50); however, these publications were not included in this study as they were often unrelated to OA or older adults. Kneer, et al51 recently published a multiple-dose, open-label, longterm (18 months) study on the safety of topical ketoprofen (in Transfersome) in subjects (median age 63 years) with joint pain, musculoskeletal pain, stiffness, or soft tissue inflammation; 69% of the subjects were treated for OA. Erythema and pruritus were the most common AE and there were no reports of GI bleeding or “major, treatment induced changes” in laboratory values or vital signs. While this was the first study to report AE for an extended exposure, we were unable to assign AE to the subjects with OA, thus this study was excluded from our systematic review.

As the literature suggests52, in order to obtain the information needed to guide decision-making in older adults with OA, observational studies that include participants with various comorbidities (such as hypertension, diabetes, gastroesophageal reflux disease, renal insufficiency, and conditions requiring anticoagulation) are needed. Future studies should also consider the effect13,24,25,33 that the topical NSAID vehicle/carrier may have on both application site and systemic AE. Examination of drug-related effects, including vehicles used and total dose51, is also critical in order to assess tolerability.

Despite the limitations and heterogeneity of existing data, our systematic review provides important insights into the safety of topical NSAID in older adults with OA. The literature supports that topical NSAID are almost as effective and carry a lower risk of severe AE (gastrointestinal) compared to oral NSAID, although topical NSAID users do report non-life-threatening gastrointestinal events and many application site AE. While topical NSAID are safer than oral NSAID, given the AE profile and withdrawal rates we describe, further data are needed to quantify the incremental benefits of these agents compared to other treatment modalities for older adults with OA.

Acknowledgments

We thank Jan Glover from the Cushing-Whitney Yale Medical Library for her expertise in conducting the search strategy for this systematic review.

Appendix. Ovid Medline search strategy

  1. exp Anti-Inflammatory Agents, Non-Steroidal/

  2. exp Cyclooxygenase Inhibitors/

  3. exp Cyclooxygenase 2 Inhibitors/

  4. NSAIDs.tw.

  5. 1 or 2 or 3 or 4

  6. exp Administration, Topical/

  7. exp Administration, Oral/

  8. exp Pharmaceutical Solutions/

  9. exp Placebos/

  10. exp Drug Administration Schedule/

  11. 6 or 7 or 8 or 9 or 10

  12. exp Osteoarthritis/

  13. exp Arthralgia/

  14. Arthritis/

  15. osteoarthritis.tw.

  16. 12 or 13 or 14 or 15

  17. (gel or gels or solution$ or solvent$).mp.

  18. placebo$.tw.

  19. (topical adj NSAIDs).tw.

  20. exp Aged/

  21. elderly.mp.

  22. (aged or geriatric$ or seniors).tw.

  23. 11 or 17 or 18 or 19

  24. 20 or 21 or 22

  25. 5 and 23 and 16 and 24

  26. randomized controlled trial.pt.

  27. controlled clinical trial.pt.

  28. randomized controlled trials.sh.

  29. random allocation.sh.

  30. double blind method.sh.

  31. single blind method.sh.

  32. 26 or 27 or 28 or 29 or 30 or 31

  33. (animals not humans).sh.

  34. 32 not 33

  35. clinical trial.pt.

  36. exp Clinical Trial/

  37. (clin$ adj25 trial$).ti,ab.

  38. ((singl$ or doubl$ or trebl$ or tripl$) adj25 (blind$ or mask$)).ti,ab.

  39. placebos.sh.

  40. placebo$.ti,ab.

  41. random$.ti,ab.

  42. research design.sh.

  43. 35 or 36 or 37 or 38 or 39 or 40 or 41 or 42

  44. 43 not 33

  45. 44 not 34

  46. comparative study.sh.

  47. exp evaluation studies/

  48. follow up studies.sh.

  49. prospective studies.sh.

  50. (control$ or prospectiv$ or volunteer$).ti,ab.

  51. 46 or 47 or 48 or 49 or 50

  52. 51 not 33

  53. 52 not (34 or 45)

Footnotes

  • Dr. Makris is supported by the National Institute on Aging T32 AG19134 Training Program in Aging Related Research and Clinical Epidemiology. Dr. Fraenkel receives support from NIAMS K23 AR048826.

  • Accepted for publication January 7, 2010.

REFERENCES

  1. 1.↵
    1. Dawson J,
    2. Linsell L,
    3. Zondervan K,
    4. Rose P,
    5. Randall T,
    6. Carr A,
    7. et al.
    Epidemiology of hip and knee pain and its impact on overall health status in older adults. Rheumatology 2004;43:497–504.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Peat G,
    2. McCarney R,
    3. Croft P
    . Knee pain and osteoarthritis in older adults: a review of community burden and current use of primary health care. Ann Rheum Dis 2001;60:91–7.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Felson DT
    . The epidemiology of knee osteoarthritis: results from the Framingham Osteoarthritis Study. Semin Arthritis Rheum 1990;20:42–50.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Bellamy N,
    2. Kirwan J,
    3. Boers M,
    4. Brooks P,
    5. Strand V,
    6. Tugwell P,
    7. et al.
    Recommendations for a core set of outcome measures for future phase III clinical trials in knee, hip, and hand osteoarthritis. Consensus development at OMERACT III. J Rheumatol 1997;24:799–802.
    OpenUrlPubMed
  5. 5.↵
    1. Bateman DN,
    2. Kennedy JG
    . Non-steroidal anti-inflammatory drugs and elderly patients. BMJ 1995;310:817–8.
    OpenUrlFREE Full Text
  6. 6.↵
    1. Zhang W,
    2. Moskowitz RW,
    3. Nuki G,
    4. Abramson S,
    5. Altman RD,
    6. Arden N,
    7. et al.
    OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage 2008;16:137–62.
    OpenUrlCrossRefPubMed
  7. 7.↵
    American Academy of Orthopaedic Surgeons: Treatment of osteoarthritis of the knee (non-arthroplasty). [Internet. Accessed February 19, 2010.] Available from: http://www.aaos.org/Research/guidelines/GuidelineOAKnee.asp
  8. 8.↵
    1. Dickson DJ
    . A double-blind evaluation of topical piroxicam gel with oral ibuprofen in osteoarthritis of the knee. Curr Ther Res Clin Exp 1991;49:199–207.
    OpenUrl
  9. 9.↵
    1. Rother M,
    2. Lavins BJ,
    3. Kneer W,
    4. Lehnhardt K,
    5. Seidel EJ,
    6. Mazgareanu S
    . Efficacy and safety of epicutaneous ketoprofen in Transfersome (IDEA-033) versus oral celecoxib and placebo in osteoarthritis of the knee: multicentre randomised controlled trial. Ann Rheum Dis 2007;66:1178–83.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Tugwell PS,
    2. Wells GA,
    3. Shainhouse JZ
    . Equivalence study of a topical diclofenac solution (Pennsaid) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial. J Rheumatol 2004;31:2002–12.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Sandelin J,
    2. Harilainen A,
    3. Crone H,
    4. Hamberg P,
    5. Forsskahl B,
    6. Tamelander G
    . Local NSAID gel (Eltenac) in the treatment of osteoarthritis of the knee. A double blind study comparing Eltenac with oral diclofenac and placebo gel. Scand J Rheumatol 1997;26:287–92.
    OpenUrlPubMed
  12. 12.↵
    1. Underwood M,
    2. Ashby D,
    3. Cross P,
    4. Hennessy E,
    5. Letley L,
    6. Martin J,
    7. et al.
    Advice to use topical or oral ibuprofen for chronic knee pain in older people: randomised controlled trial and patient preference study. BMJ 2008;336:138–42.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Simon LS,
    2. Grierson LM,
    3. Naseer Z,
    4. Bookman AA,
    5. Zev Shainhouse J
    . Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis. Pain 2009;143:238–45.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Fraenkel L,
    2. Wittink DR,
    3. Concato J,
    4. Fried T
    . Informed choice and the widespread use of antiinflammatory drugs. Arthritis Rheum 2004;51:210–4.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Andrews PA,
    2. Sampson SA
    . Topical non-steroidal drugs are systemically absorbed and may cause renal disease. Nephrol Dial Transpl 1999;14:187–9.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Garcia Rodriguez LA,
    2. Jick H
    . Risk of upper gastrointestinal bleeding and perforation associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:769–72.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Langman MJ,
    2. Weil J,
    3. Wainwright P,
    4. Lawson DH,
    5. Rawlins MD,
    6. Logan RF,
    7. et al.
    Risks of bleeding peptic ulcer associated with individual non-steroidal anti-inflammatory drugs. Lancet 1994;343:1075–8.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Gabriel SE,
    2. Jaakkimainen L,
    3. Bombardier C
    . Risk for serious gastrointestinal complications related to use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991;115:787–96.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Jick H,
    2. Derby LE,
    3. Garcia Rodriguez LA,
    4. Jick SS,
    5. Dean AD
    . Liver disease associated with diclofenac, naproxen, and piroxicam. Pharmacotherapy 1992;12:207–12.
    OpenUrlPubMed
  20. 20.↵
    1. Ophaswongse S,
    2. Maibach H
    . Topical nonsteroidal antiinflammatory drugs: allergic and photoallergic contact dermatitis and phototoxicity. Contact Dermatitis 1993;29:57–64.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Zimmerman J,
    2. Siguencia J,
    3. Tsvang E
    . Upper gastrointestinal hemorrhage associated with cutaneous application of diclofenac gel. Am J Gastroenterol 1995;90:2032–4.
    OpenUrlPubMed
  22. 22.↵
    1. Evans JMM,
    2. MacDonald TM
    . Tolerability of topical NSAIDs in the elderly — Do they really convey a safety advantage? Drug Aging 1996;9:101–8.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Evans JM,
    2. McMahon AD,
    3. McGilchrist MM,
    4. White G,
    5. Murray FE,
    6. McDevitt DG,
    7. et al.
    Topical non-steroidal anti-inflammatory drugs and admission to hospital for upper gastrointestinal bleeding and perforation: a record linkage case-control study. BMJ 1995;311:22–6.
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Baer PA,
    2. Thomas LM,
    3. Shainhouse Z
    . Treatment of osteoarthritis of the knee with a topical diclofenac solution: a randomised controlled, 6-week trial. BMC Musculoskelet Disord 2005;6:44.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Bookman AA,
    2. Williams KS,
    3. Shainhouse JZ
    . Effect of a topical diclofenac solution for relieving symptoms of primary osteoarthritis of the knee: a randomized controlled trial. CMAJ 2004;171:333–8.
    OpenUrlAbstract/FREE Full Text
  26. 26.↵
    1. Bruhlmann P,
    2. Michel BA
    . Topical diclofenac patch in patients with knee osteoarthritis: a randomized, double-blind, controlled clinical trial. Clin Exp Rheumatol 2003;21:193–8.
    OpenUrlPubMed
  27. 27.↵
    1. Chow WH,
    2. Cheung KL,
    3. Ling HM,
    4. See T
    . Potentiation of warfarin anticoagulation by topical methylsalicylate ointment. J R Soc Med 1989;82:501–2.
    OpenUrlFREE Full Text
  28. 28.↵
    1. Cooper SM,
    2. Shaw S
    . Contact allergy to isopropanolamine in Traxam® gel. Contact Dermatitis 1999;41:233–4.
    OpenUrlPubMed
  29. 29.↵
    1. Dreiser RL,
    2. Tisne-Camus M
    . DHEP plasters as a topical treatment of knee osteoarthritis — a double-blind placebo-controlled study. Drug Exp Clin Res 1993;19:117–23.
    OpenUrl
  30. 30.↵
    1. Grace D,
    2. Rogers J,
    3. Skeith K,
    4. Anderson K
    . Topical diclofenac versus placebo: a double blind, randomized clinical trial in patients with osteoarthritis of the knee. J Rheumatol 1999;26:2659–63.
    OpenUrlPubMed
  31. 31.↵
    1. Niethard FU,
    2. Gold MS,
    3. Solomon GS,
    4. Liu J-M,
    5. Unkauf M,
    6. Albrecht HH,
    7. et al.
    Efficacy of topical diclofenac diethylamine gel in osteoarthritis of the knee. J Rheumatol 2005;32:2384–92.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    1. Ottillinger B,
    2. Gomor B,
    3. Michel BA,
    4. Pavelka K,
    5. Beck W,
    6. Elsasser U
    . Efficacy and safety of Eltenac gel in the treatment of knee osteoarthritis. Osteoarthritis Cartilage 2001;9:273–80.
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Roth SH,
    2. Shainhouse JZ
    . Efficacy and safety of a topical diclofenac solution (Pennsaid) in the treatment of primary osteoarthritis of the knee: a randomized, double-blind, vehicle-controlled clinical trial. Arch Intern Med 2004;164:2017–23.
    OpenUrlCrossRefPubMed
  34. 34.↵
    1. Waikakul S,
    2. Penkitti P,
    3. Soparat K,
    4. Boonsanong W
    . Topical analgesics for knee arthrosis: A parallel study of ketoprofen gel and diclofenac emulgel. J Med Assoc Thailand 1997;80:593–7.
    OpenUrlPubMed
  35. 35.↵
    1. Widrig R,
    2. Suter A,
    3. Saller R,
    4. Melzer J
    . Choosing between NSAID and arnica for topical treatment of hand osteoarthritis in a randomised, double-blind study. Rheumatol Int 2007;27:585–91.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Yip AS,
    2. Chow WH,
    3. Tai YT,
    4. Cheung KL
    . Adverse effect of topical methylsalicylate ointment on warfarin anticoagulation: an unrecognized potential hazard. Postgrad Med J 1990;66:367–9.
    OpenUrlAbstract/FREE Full Text
  37. 37.↵
    1. Altman RD,
    2. Dreiser RL,
    3. Fisher CL,
    4. Chase WF,
    5. Dreher DS,
    6. Zacher J
    . Diclofenac sodium gel in patients with primary hand osteoarthritis: a randomized, double-blind, placebo-controlled trial. J Rheumatol 2009;36:1991–9.
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    1. Jadad AR,
    2. Moore RA,
    3. Carroll D,
    4. Jenkinson C,
    5. Reynolds DJ,
    6. Gavaghan DJ,
    7. et al.
    Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1–12.
    OpenUrlCrossRefPubMed
  39. 39.↵
    1. Mason L,
    2. Moore RA,
    3. Edwards JE,
    4. Derry S,
    5. McQuay HJ
    . Topical NSAIDs for chronic musculoskeletal pain: systematic review and meta-analysis. BMC Musculoskelet Disord 2004;5:28.
    OpenUrlCrossRefPubMed
  40. 40.↵
    1. Mason L,
    2. Moore RA,
    3. Edwards JE,
    4. Derry S,
    5. McQuay HJ
    . Topical NSAIDs for acute pain: a meta-analysis. BMC Fam Pract 2004;5:10.
    OpenUrlCrossRefPubMed
  41. 41.↵
    1. Moore RA,
    2. Tramer MR,
    3. Carroll D,
    4. Wiffen PJ,
    5. McQuay HJ
    . Quantitive systematic review of topically applied non-steroidal anti-inflammatory drugs. BMJ 1998;316:333–8.
    OpenUrlAbstract/FREE Full Text
  42. 42.↵
    1. Zacher J,
    2. Altman R,
    3. Bellamy N,
    4. Bruhlmann P,
    5. Da Silva J,
    6. Huskisson E,
    7. et al.
    Topical diclofenac and its role in pain and inflammation: an evidence-based review. Curr Med Res Opin 2008;24:925–50.
    OpenUrlCrossRefPubMed
  43. 43.↵
    1. Towheed TE
    . Pennsaid® therapy for osteoarthritis of the knee: A systematic review and metaanalysis of randomized controlled trials. J Rheumatol 2006;33:567–73.
    OpenUrlAbstract/FREE Full Text
  44. 44.↵
    1. Touma Z,
    2. Chen L,
    3. Arayssi T
    . Topical nonsteroidal anti-inflammatory drugs in the treatment of osteoarthritis. Future Rheumatol 2007;2:163–75.
    OpenUrlCrossRef
  45. 45.↵
    1. Petersen B,
    2. Rovati S
    . Diclofenac epolamine (Flector) patch: evidence for topical activity. Clin Drug Investig 2009;29:1–9.
    OpenUrlPubMed
  46. 46.↵
    Novartis. Prescribing information for Voltaren Gel (diclofenac sodium topical gel). 2007.
  47. 47.↵
    1. Rainsford KD,
    2. Kean WF,
    3. Ehrlich GE
    . Review of the pharmaceutical properties and clinical effects of the topical NSAID formulation, diclofenac epolamine. Curr Med Res Opin 2008;24:2967–92.
    OpenUrlCrossRefPubMed
  48. 48.↵
    1. Rochon PA,
    2. Fortin PR,
    3. Dear KB,
    4. Minaker KL,
    5. Chalmers TC
    . Reporting of age data in clinical trials of arthritis. Deficiencies and solutions. Arch Intern Med 1993;153:243–8.
    OpenUrlCrossRefPubMed
  49. 49.↵
    1. Liberopoulos G,
    2. Trikalinos NA,
    3. Ioannidis JP
    . The elderly were under-represented in osteoarthritis clinical trials. J Clin Epidemiol 2009;62:1218–23.
    OpenUrlCrossRefPubMed
  50. 50.↵
    1. Diaz RL,
    2. Gardeazabal J,
    3. Manrique P,
    4. Raton JA,
    5. Urrutia I,
    6. Rodriguez-Sasiain JM,
    7. et al.
    Greater allergenicity of topical ketoprofen in contact dermatitis confirmed by use. Contact Dermatitis 2006;54:239–43.
    OpenUrlCrossRefPubMed
  51. 51.↵
    1. Kneer W,
    2. Rother I,
    3. Rother M,
    4. Seidel E
    . A multiple-dose, open-label, safety, compliance, and usage evaluation study of epicutaneously applied Diractin (ketoprofen in Transfersome) in joint/musculoskeletal pain or soft tissue inflammation. Curr Drug Saf 2009;4:5–10.
    OpenUrlCrossRefPubMed
  52. 52.↵
    1. Vandenbroucke JP,
    2. Psaty BM
    . Benefits and risks of drug treatments: how to combine the best evidence on benefits with the best data about adverse effects. JAMA 2008;300:2417–9.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 37, Issue 6
1 Jun 2010
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Adverse Effects of Topical Nonsteroidal Antiinflammatory Drugs in Older Adults with Osteoarthritis: A Systematic Literature Review
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Adverse Effects of Topical Nonsteroidal Antiinflammatory Drugs in Older Adults with Osteoarthritis: A Systematic Literature Review
UNA E. MAKRIS, MINNA J. KOHLER, LIANA FRAENKEL
The Journal of Rheumatology Jun 2010, 37 (6) 1236-1243; DOI: 10.3899/jrheum.090935

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Adverse Effects of Topical Nonsteroidal Antiinflammatory Drugs in Older Adults with Osteoarthritis: A Systematic Literature Review
UNA E. MAKRIS, MINNA J. KOHLER, LIANA FRAENKEL
The Journal of Rheumatology Jun 2010, 37 (6) 1236-1243; DOI: 10.3899/jrheum.090935
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Save to my folders

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Acknowledgments
    • Appendix. Ovid Medline search strategy
    • Footnotes
    • REFERENCES
  • Figures & Data
  • References
  • Info & Metrics
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Composite Measures for Clinical Trials in Psoriatic Arthritis: Testing Pain and Fatigue Modifications in a UK Multicenter Study
  • GRAPPA Patient Research Partner Network: Update to the GRAPPA 2020 Annual Meeting
  • Instruments Measuring Physical Function for Psoriatic Arthritis Endorsed at GRAPPA 2020 Annual Meeting: Updates of the GRAPPA-OMERACT Working Group
Show more Articles

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2016 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire